PTGS2 and myeloid sarcoma: We found COX2 immunoreactivity predominantly in larger vessels (panel 1, Fig. 2f) but predominantly around numerous nuclei expressing CD45 (panel 2), which we confirmed using confocal imaging (Fig. S1e), both in NNC and MS cases (Fig. 2f).